Oxidative stress may play an important role in both initiation and progression of breast cancer. We conducted the first systematic epidemiologic review to summarize the published literature on oxidative stress biomarkers and breast cancer.
Materials and Methods:
We implemented systematic search strategies to identify published studies of oxidative stress biomarkers and (1) risk of developing breast cancer and (2) breast cancer prognosis using the PRISMA statement guidelines.
Results:
We identified eleven case–control studies of oxidative stress biomarkers and breast cancer. Biomarkers utilized varied and menopausal status was a key modifying factor. Across three nested case–control studies with biomarkers measured before diagnosis, one reported increased risk of postmenopausal breast cancer in association with 8-oxodG (DNA damage biomarker), while two (one of F2-isoprostanes and one of fluorescent oxidation products) reported inverse associations for premenopausal breast cancer only. We identified eight prognostic studies. Two reported associations for lipid peroxidation and breast cancer prognosis; results for other studies were null.
Conclusions:
DNA damage may increase risk of breast cancer among postmenopausal women, while lipid peroxidation may be inversely associated with premenopausal breast cancer. Lipid peroxidation may be associated with survival after breast cancer diagnosis; however, results require evaluation in large, prospective cohort studies.
Get full access to this article
View all access options for this article.
References
1.
MaritimAC, SandersRA, WatkinsJBIII.Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol, 2003; 17:24–38.
2.
KlaunigJE, KamendulisLM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol, 2004; 44:239–267.
3.
BasuS. F2-isoprostanes in human health and diseases: From molecular mechanisms to clinical implications. Antioxid Redox Signal, 2008; 10:1405–1434.
4.
ElahiMM, KongYX, MatataBM. Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev, 2009; 2:259–269.
5.
HalliwellB, GutteridgeJM. Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts. Arch Biochem Biophys, 1986; 246:501–514.
6.
SiesH. Oxidative stress: Oxidants and antioxidants. Exp Physiol, 1997; 82:291–295.
7.
MayneST. Antioxidant nutrients and chronic disease: Use of biomarkers of exposure and oxidative stress status in epidemiologic research. J Nutr, 2003; 133:933s–940s.
8.
BrownNS, BicknellR. Hypoxia and oxidative stress in breast cancer—Oxidative stress: Its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res, 2001; 3:323–327.
9.
Vera-RamirezL, Sanchez-RoviraP, Ramirez-TortosaMC, et al.Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies. Crit Rev Oncol Hematol, 2011; 80:347–368.
10.
Echiburu-ChauC, RoyD, CalafGM. Metastatic suppressor CD44 is related with oxidative stress in breast cancer cell lines. Int J Oncol, 2011; 39:1481–1489.
11.
GorriniC, HarrisIS, MakTW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov, 2013; 12:931–947.
12.
LawendaBD, KellyKM, LadasEJ, et al.Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?. J Natl Cancer Inst, 2008; 100:773–783.
13.
SangeethaP, DasUN, KoratkarR, SuryaprabhaP. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Rad Biol Med, 1990; 8:15–19.
14.
WeijlNI, CletonFJ, OsantoS. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev, 1997; 23:209–240.
Dalle-DonneI, RossiR, ColomboR, GiustariniD, MilzaniA. Biomarkers of oxidative damage in human disease. Clin Chem, 2006; 52:601–623.
17.
GiustariniD, Dalle-DonneI, TsikasD, RossiR. Oxidative stress and human diseases: Origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci, 2009; 46:241–281.
18.
OginoK, WangDH. Biomarkers of oxidative/nitrosative stress: An approach to disease prevention. Acta Med Okayama, 2007; 61:181–189.
19.
ValavanidisA, VlachogianniT, FiotakisC. 8-hydroxy-2′-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 2009; 27:120–139.
20.
WuTY, WillettWC, RifaiN, RimmEB. Plasma fluorescent oxidation products as potential markers of oxidative stress for epidemiologic studies. Am J Epidemiol, 2007; 166:552–560.
21.
RobertsLJ, MorrowJD. Measurement of F-2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med, 2000; 28:505–513.
22.
OlinskiR, GackowskiD, RozalskiR, FoksinskiM, BialkowskiK. Oxidative DNA damage in cancer patients: A cause or a consequence of the disease development?. Mutation Res, 2003; 531:177–190.
23.
Dalle-DonneI, RossiR, GiustariniD, MilzaniA, ColomboR. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta, 2003; 329:23–38.
24.
KadiiskaMB, GladenBC, BairdDD, et al.Biomarkers of oxidative stress study II. Are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Radic Biol Med, 2005; 38:698–710.
25.
KnasmullerS, NersesyanA, MisikM, et al.Use of conventional and -omics based methods for health claims of dietary antioxidants: A critical overview. Br J Nutr, 2008; 99 ESuppl 1:ES3–ES52.
26.
MilneGL, YinH, MorrowJD. Human biochemistry of the isoprostane pathway. J Biol Chem, 2008; 283:15533–15537.
27.
HalliwellB, LeeCYJ. Using isoprostanes as biomarkers of oxidative stress: Some rarely considered issues. Antioxid Redox Signal, 2010; 13:145–156.
28.
FortnerRT, TworogerSS, WuT, EliassenAH. Plasma florescent oxidation products and breast cancer risk: Repeated measures in the Nurses' Health Study. Breast Cancer Res Treat, 2013; 141:307–316.
29.
SakhiAK, RussnesKM, ThoresenM, et al.Pre-radiotherapy plasma carotenoids and markers of oxidative stress are associated with survival in head and neck squamous cell carcinoma patients: A prospective study. BMC Cancer, 2009; 9:458.
30.
LoftS, OlsenA, MollerP, PoulsenHE, TjonnelandA. Association between 8-oxo-7,8-dihydro-2′-deoxyguanosine excretion and risk of postmenopausal breast cancer: Nested case-control study. Cancer Epidemiol Biomarkers Prev, 2013; 22:1289–1296.
31.
RossnerPJr, TerryMB, GammonMD, et al.Plasma protein carbonyl levels and breast cancer risk. J Cell Mol Med, 2007; 11:1138–1148.
32.
LeufkensAM, van DuijnhovenFJB, WoudtSHS, et al.Biomarkers of oxidative stress and risk of developing colorectal cancer: A cohort-nested case-control study in the european prospective investigation into cancer and nutrition. Am J Epidemiol, 2012; 175:653–663.
33.
KrystonTB, GeorgievAB, PissisP, GeorgakilasAG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutation Res, 2011; 711:193–201.
34.
AmbrosoneCB. Oxidants and antioxidants in breast cancer. Antioxidants Redox Signal, 2000; 2:903–917.
35.
Jezierska-DrutelA, RosenzweigSA, NeumannCA. Role of oxidative stress and the microenvironment in breast cancer development and progression. Adv Cancer Res, 2013; 119:107–125.
36.
DorjgochooT, GaoYT, ChowWH, et al.Obesity, age, and oxidative stress in middle-aged and older women. Antioxidants Redox Signal, 2011; 14:2453–2460.
37.
KeaneyJF, LarsonMG, VasanRS, et al.Obesity and systemic oxidative stress—Clinical correlates of oxidative stress in the Framingham Study. Arterioscl Thromb Vasc, 2003; 23:434–439.
38.
MoherD, LiberatiA, TetzlaffJ, AltmanDG, GroupP. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med, 2009; 6:e1000097.
39.
OhB, FigtreeG, CostaD, et al.Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate Int, 2016; 4:71–87.
40.
RossnerPJr., GammonMD, TerryMB, et al.Relationship between urinary 15-F2t-isoprostane and 8-oxodeoxyguanosine levels and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 2006; 15:639–644.
41.
ShenJ, GammonMD, TerryMB, et al.Telomere length, oxidative damage, antioxidants and breast cancer risk. Int J Cancer, 2009; 124:1637–1643.
42.
ZipprichJ, TerryMB, LiaoY, et al.Plasma protein carbonyls and breast cancer risk in sisters discordant for breast cancer from the New York site of the Breast Cancer Family Registry. Cancer Res, 2009; 69:2966–2972.
43.
SharharS, NormahH, FatimahA, et al.Antioxidant intake and status, and oxidative stress in relation to breast cancer risk: A case-control study. Asian Pac J Cancer Prev, 2008; 9:343–349.
44.
SmithTR, MillerMS, LohmanKK, CaseLD, HuJJ. DNA damage and breast cancer risk. Carcinogenesis, 2003; 24:883–889.
45.
DaiQ, GaoYT, ShuXO, et al.Oxidative stress, obesity, and breast cancer risk: Results from the Shanghai Women's Health Study. J Clin Oncol, 2009; 27:2482–2488.
46.
LeeKH, ShuXO, GaoYT, et al.Breast cancer and urinary biomarkers of polycyclic aromatic hydrocarbon and oxidative stress in the Shanghai Women's Health Study. Cancer Epidemiol Biomarkers Prev, 2010; 19:877–883.
47.
SistiJS, LindstromS, KraftP, et al.Premenopausal plasma carotenoids, fluorescent oxidation products, and subsequent breast cancer risk in the nurses' health studies. Breast Cancer Res Treat, 2015; 151:415–425.
48.
SaintotM, Mathieu-DaudeH, AstreC, et al.Oxidant-antioxidant status in relation to survival among breast cancer patients. Int J Cancer, 2002; 97:574–579.
49.
SovaH, Jukkola-VuorinenA, PuistolaU, KauppilaS, KarihtalaP. 8-Hydroxydeoxyguanosine: A new potential independent prognostic factor in breast cancer. Br J Cancer, 2010; 102:1018–1023.
50.
KarihtalaP, KauppilaS, SoiniY, Arja JukkolaV. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer, 2011; 11:262.
51.
KarihtalaP, KauppilaS, PuistolaU, Jukkola-VuorinenA. Absence of the DNA repair enzyme human 8-oxoguanine glycosylase is associated with an aggressive breast cancer phenotype. Br J Cancer, 2012; 106:344–347.
52.
Vera-RamirezL, Sanchez-RoviraP, Ramirez-TortosaMC, et al.Does chemotherapy-induced oxidative stress improve the survival rates of breast cancer patients?. Antioxid Redox Signal, 2011; 15:903–909.
53.
Vera-RamirezL, Sanchez-RoviraP, Ramirez-TortosaMC, et al.Oxidative stress status in metastatic breast cancer patients receiving palliative chemotherapy and its impact on survival rates. Free Radic Res, 2012; 46:2–10.
54.
NechutaS, CaiQ, ZhengY, et al.Urinary biomarkers of oxidative stress and breast cancer survival. Cancer Causes Cont, 2014; 25:701–707.
55.
ThomsonCA, GiulianoAR, ShawJW, et al.Diet and biomarkers of oxidative damage in women previously treated for breast cancer. Nutr Cancer, 2005; 51:146–154.
56.
BlockG, DietrichM, NorkusEP, et al.Factors associated with oxidative stress in human populations. Am J Epidemiol, 2002; 156:274–285.
57.
CrujeirasAB, Diaz-LagaresA, CarreiraMC, AmilM, CasanuevaFF. Oxidative stress associated to dysfunctional adipose tissue: A potential link between obesity, type 2 diabetes mellitus and breast cancer. Free Radic Res, 2013; 47:243–256.
58.
MunsellMF, SpragueBL, BerryDA, ChisholmG, Trentham-DietzA. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev, 2014; 36:114–136.
59.
LambertiniM, SantoroL, Del MastroL, et al.Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. Cancer Treat Rev, 2016; 49:65–76.
60.
PhippsAI, IchikawaL, BowlesEJ, et al.Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates. Maturitas, 2010; 67:60–66.
61.
WeimannA, BroedbaekK, HenriksenT, StovgaardES, PoulsenHE. Assays for urinary biomarkers of oxidatively damaged nucleic acids. Free Radic Res, 2012; 46:531–540.
62.
MilneGL, SanchezSC, MusiekES, MorrowJD. Quantification of F-2-isoprostanes as a biomarker of oxidative stress. Nat Protoc, 2007; 2:221–226.
63.
WattersJL, SatiaJA, KupperLL. Correlates of antioxidant nutrients and oxidative DNA damage differ by race in a cross-sectional study of healthy African American and white adults. Nutr Res, 2008; 28:565–576.
64.
RoszkowskiK, OlinskiR. Urinary 8-oxoguanine as a predictor of survival in patients undergoing radiotherapy. Cancer Epidemiol Biomarkers Prev, 2012; 21:629–634.
